Dr Dipak Kotecha

Dr Dipak Kotecha

Institute of Cardiovascular Sciences
NIHR Clinical Lecturer in Cardiovascular Medicine

Contact details

Institute of Cardiovascular Sciences
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Dipak is a Clinician Scientist in Cardiovascular Medicine across the clinical sites attached to the University of Birmingham. He is also an Honorary Research Fellow at the Monash Centre of Cardiovascular Research & Education in Therapeutics, Monash University, Melbourne.  He is a Consultant Cardiologist specialising in cardiac imaging, and is accredited in transthoracic and transoesophageal echocardiography (British Society of Echocardiography), and cardiac magnetic resonance imaging (EuroCMR Level 3).

Dipak was recently awarded a prestigious National Institute for Health Research (NIHR) Fellowship.  This funding will allow him to expand his internationally-recognised research on patients with heart failure and atrial fibrillation.  The Fellowship funds a new randomised controlled trial with the aim of improving quality of life and heart function in patients with atrial fibrillation and breathlessness (the RATE-AF trial: RAte control Therapy Evaluation in Atrial Fibrillation).

Among other projects, Dipak is also the lead for the Beta-blockers in Heart Failure Collaborative Group and has published in leading journals such as the Lancet and BMJ (see below).  He regularly presents at major international conferences, works with the European Society of Cardiology, and is focused on developing robust statistical evaluations and clinical trials. 


  • Bachelor of Medicine, Bachelor of Surgery; MBChB 2000: University of Bristol
  • Member of the Royal College of Physicians (London); MRCP 2004
  • Doctor of Philosophy; PhD 2010: National Heart & Lung Institute, Imperial College London
  • Fellow of the European Society of Cardiology; FESC 2015
  • Fellow of the Higher Education Academy; FHEA 2015


Dipak studied Medicine at the University of Bristol and trained as a junior doctor in the south-west of England.  After gaining Membership of the Royal College of Physicians in 2004 he departed for Australia to gain further clinical and academic experience.  He worked as a Cardiology Registrar in Melbourne for 2 years before starting his PhD studies. Registered at the National Heart & Lung Institute, Imperial College London, the PhD was an international collaborative project with the Royal Brompton Hospital in London (Prof Marcus Flather) and Monash University in Melbourne (Prof Henry Krum). After completing his PhD, Dipak re-joined the NHS in 2009 and was a clinical trainee in Oxford, specialising in cardiac imaging. During this time he continued his academic work, leading to his appointment as a Clinical Lecturer here in Birmingham, and subsequently appointment as a Clinician Scientist and Consultant Cardiologist at the University Hospitals Birmingham NHS Trust and Sandwell & West Birmingham Hospitals NHS Trust.  Dipak was awarded Fellowship of the European Society of Cardiology (ESC) for his work in the prevention and management of cardiovascular disease, and Fellowship of the Higher Education Academy for his teaching.  In 2016, he commenced his NIHR Career Development Fellowship designed to improve patient wellbeing in those needing rate control for atrial fibrillation


  • MD / PhD students and research fellows
  • Clinical teaching
  • International lectures on heart failure, atrial fibrillation and statistical methods

Postgraduate supervision

  • Supervision of MD / PhD students.
  • Supervision of research fellows.
  • Applications welcome.


Lead: RAte control Therapy Evaluation in Atrial Fibrillation (RATE-AF) trial.

NIHR-funded randomised trial of rate-control in older patients with permanent atrial fibrillation, assessing the impact of therapy on quality of life and cardiac function.  Other research includes analysis of pharmacotherapy; systemic reviews of validity and reproducibility of echocardiography and patient-reported outcomes in atrial fibrillation; secondary analyses of trial and general practice datasets; and Medical Research Council co-funded PhD studentship investigating cellular and translational mechanisms of rate control atrial fibrillation.

Co-ordinator and Steering Committee Lead: Beta Blockers in Heart Failure Collaborative Group (BB-meta-HF).

A global collaboration of lead investigators and pharmaceutical companies involved in the major trials of beta-blockers in heart failure to undertake a meta-analysis of individual patient data (n=18630).  Hotline presentations at the European Society of Cardiology (ESC) Congress in Barcelona 2014 (patients with concomitant atrial fibrillation) and London 2015 (analysis of age and gender), with publications in the Lancet and BMJ.

Principal Investigator: Alternative Risk Markers in Coronary Artery Disease (ARM-CAD) Study.

Multi-centre research study to assess vascular dysfunction and angiographic coronary artery disease in high-risk populations (n=700).  PhD awarded 2010: “Evaluation of Pulse Wave Analysis to Assess Coronary Artery Disease”.

Principal Investigator and co-creator of the Cardiovascular Longitudinal Evaluation & Assessment of Risk (CLEAR) Database.

Cross-research database to incorporate current and future investigator-driven studies, improve data collection, standardise cardiovascular risk information and enhance recruitment into research projects.  Commenced recruitment 2007 (currently n=4500).

Other activities

  • 2016                 Faculty member, Europe AF 2016, London (Nov)
  • 2016                 Faculty member, British Society of Echo Annual Conference, London (Nov)
  • 2016                 Faculty member, AF Heart Team, Switzerland (Sept)
  • 2016                 Faculty member, European Society of Cardiology Congress, Rome (Aug)
  • 2016                 Guest Lecture, MSc in Health Economics (ESC/LSE), London (June)
  • 2016                 Faculty member, EuroCVP Cardiovascular Pharmacotherapy, Tel Aviv
  • 2016                 Faculty member, Heart Failure 2016, Florence
  • 2016                 Faculty member, Navigating the Maze Summit, Barcelona
  • 2016                 Award: One of the most popular articles published in the European Heart Journal in 2015 (downloaded 5320 times in the first two months of publication)
  • 2015                 All Party Parliamentary Group on Atrial Fibrillation, Houses of Parliament, London
  • 2015                 Faculty member, European Society of Cardiology Congress, London
  • 2015                 Faculty member, Physicians’ Academy for Cardiovascular Education (PACE) Foundation Heart Failure Summit, Barcelona
  • 2015                 Faculty member, British Cardiovascular Society Annual Conference, Manchester
  • 2015                 Faculty member, Heart Failure 2015 Congress, Seville
  • 2015-6             TEAM in AF European Mentoring Programme for future leaders in atrial fibrillation
  • 2015                 Faculty member, European Association of Cardiothoracic Surgery Course, Windsor
  • 2015                 Consensus Statements on Atrial Fibrillation; EHRA/AFNET 5th Consensus Conference
  • 2014-6             Guideline Task Force for Atrial Fibrillation; European Society of Cardiology
  • 2013-15           National Institute for Health Research Leadership Programme; Ashridge Business School
  • 2013                 Postgraduate Certificate of Academic Practice; University of Birmingham


Kotecha D, Manzano L, Packer M, Rosano G, Collins P, Krum H, Holmes J, Altman DG, Wikstrand J, Coats AJS, Cleland JGF, von Lueder TG, Rigby A, Shibata MC, Andersson B, Kirchhof P, Wedel H, Lip GYH and Flather MD.  Age and gender differences in treatment efficacy and tolerability: The Beta-blockers in Heart Failure Collaborative Group.  BMJ.  2016;353:i1855.  PMID: 27098105.  

Kotecha D*. Conflicting and unresolved issue of the prognostic value of atrial fibrillation for chronic heart failure patients (Letter). Int J Cardiol.  In press.  DOI: 10.1016/j.ijcard.2016.03.107.  PMID: 27087520.  

Ziff OJ and Kotecha D. Digoxin: the good and the badTrends Cardiovasc MedIn press; DOI: 10.1016/j.tcm.2016.03.011.  

Hopper I, Kotecha D, Lee Chin K, Mentz RJ, von Lueder TG*.  Comorbidities in heart failure: Are there gender differences?  Curr Heart Fail Rep.  2016;13:1-12.  PMID: 26829930.  

Kotecha D, Chudasama R, Lane DA, Kirchhof P and Lip GYH.  Atrial fibrillation and heart failure: A systematic review and meta-analysis of clinical outcomes in reduced versus preserved ejection fraction.  Int J Cardiol.  2016;203:660-6.  PMID: 26580351.  

Kirchhof P*, Breithardt G, Kotecha D and Camm AJ.  A roadmap to improve the quality of atrial fibrillation management: Proceedings from the 5th AFNET/EHRA consensus conference.  Europace.  DOI: 10.1093/europace/euv304.  PMID: 26481149.  

Kotecha D and Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;10.1093/eurheartj/ehv513  

Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J and Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451

Senoo K, Lip GYH*, Lane DA, Büller HR, Kotecha D.  Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS TrialStroke. 2015;46:2523-8.  PMID: 26205373.  

Kotecha D* and von Leuder TG.  Qualifying the use of common cardiovascular drugs in cardiology: Time to think again about beta-blockers?  Circ J. 2015;79:517-518.  PMID: 25746532.